DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
20 août 2019 13h17 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....